High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer

British Journal of Surgery

Volumn 96, Issue 12, 2009, Pages 1443-1451

  Vidal, O ^a   Metges, J P ^c   Elizalde, I ^a   Valentini M ^a   Volant, A ^d   Molina, R ^a   Castells, A ^a   Pera, M ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c Institut National de la Santé et de la Recherche Médicale Brest France   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MITOMYCIN C; UFT; UROKINASE; VASCULOTROPIN;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL DECISION MAKING; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERCUTANEOUS DRAINAGE; POSTOPERATIVE COMPLICATION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STOMACH CANCER; SURVIVAL; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 72249094330     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6780     Document Type: Article

References (40)

1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027. (Pubitemid 46202320)
2. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22. (Pubitemid 27314632)
3. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858-863. (Pubitemid 26061277)
4. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004; 90: 206-215. (Pubitemid 38174963)
5. Saito H, Tsujitani S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery 1999; 125: 195-201. (Pubitemid 29076116)
6. Ichikura T, Tomimatsu S, Ohkura E, Mochizuki H. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol 2001; 78: 132-137. (Pubitemid 32906126)
7. Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacin A, Castells A et al. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg 2008; 12: 1005-1014.
8. Luebke T, Baldus SE, Spieker D, Grass G, Bollschweiler E, Schneider PM et al. Is the urokinase-type plasminogen activator system a reliable prognostic factor in gastric cancer? Int J Biol Markers 2006; 21: 162-169. (Pubitemid 44660288)
9. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995; 13: 2084-2093.
10. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-1225. (Pubitemid 32176299)
11. Werther K, Christensen IJ, Nielsen HJ; Danish RANX05 Colorectal Cancer Study Group. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002; 86: 417-423.
12. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91: 1354-1360. (Pubitemid 39331462)
13. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236: 37-42. (Pubitemid 34686448)
14. Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH et al. Clinicopathologic significance of HIF-1 alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008; 8: 123.
15. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M. Motohashi H, Yanoma S. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000; 153: 7-12. (Pubitemid 30209837)
16. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al. (eds). AJCC Cancer Staging Manual (6th edn). Springer: New York, 2002.
17. Japanese Gastric Cancer Association. Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1: 10-24.
18. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999; 5: 487-491. (Pubitemid 29131955)
19. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6: 3147-3152.
20. Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers. A target for novel prognostic and therapeutic approaches. Ann Surg 2003; 238: 9-28. (Pubitemid 38176403)
21. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997; 79: 206-213. (Pubitemid 27029883)
22. Werther K, Christensen IJ, Brünner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000; 26: 657-662.
23. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007; 97: 978-985. (Pubitemid 47519292)
24. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80: 892-897. (Pubitemid 29209856)
25. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62: 343-350.
26. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003; 63: 3121-3126. (Pubitemid 36735862)
27. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CMet al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233: 227-235. (Pubitemid 32106077)
28. Yamamoto Y, Toi M, Kondo A, Matsumoto T, Suzuki H, Kitamura M. Concentration of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996; 2: 821-826. (Pubitemid 26168934)
29. Salven P, Mänpää H, Orpana O, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997; 3: 647-651. (Pubitemid 27244329)
30. Kitamura M, Toi M, Arai K, Iwasaki Y, Suzuki H, Matsuo K. Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol Rep 1998; 5: 1419-1424. (Pubitemid 28474087)
31. Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Syouji T et al. The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett 2003; 192: 215-225. (Pubitemid 36369276)
32. Morelli D, Lazzerini D, Cazzaniga S, Squicciarini P, Bignami P, Maier JA et al. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. Clin Cancer Res 1998; 4: 1221-1225. (Pubitemid 28213333)
33. Balsari A, Maier JA, Colnaghi MI, Ménard S. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Lab Invest 1999; 79: 897-902. (Pubitemid 29344502)
34. Beecken WD, Engl T, Hofmann J, Jonas D, Blaheta R. Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder. J Cell Mol Med 2005; 9: 655-661. (Pubitemid 44151952)
35. Gonzalez FJ, Quesada AR, Sevilla I, Baca JJ, Medina MA, Amores J et al. Prognostic value of serum angiogenic activity in colorectal cancer patients. J Cell Mol Med 2007; 11: 120-128. (Pubitemid 46439630)
36. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl JMed 2006; 355: 11-20.
37. Ychou M, Pignon JP, Lasser P. Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (C) versus surgery alone in adenocarcinoma of the stomach and lower esophagus (ASLE): FNCLCC 94012-FFCD 9703 trial. Proc Am Soc Clin Oncol 2006; 24(Suppl 18): Abstract 4026.
38. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206. (Pubitemid 46631363)
39. Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007; 60: 151-170. (Pubitemid 46742547)
40. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24. (Pubitemid 46630489)